Investors

Anaveon is backed by more than 146 million CHF (€140 million) of funding, enabling us to develop cytokine based therapies that have the potential to save patients’ lives.

Our funding includes a 150 thousand CHF award from BaseLaunch, a 1 million CHF convertible loan from University of Zurich Life Sciences Fund and 35 million CHF in Series A funding led by Syncona and joined by the Novartis Venture Fund.

In 2022, Anaveon secured a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax.

Syncona is a leading healthcare company focused on creating, building and scaling companies around exceptional science to create a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic areas, for the benefit of all stakeholders. Syncona focuses on developing treatments for patients by working in close partnership with world-class academic founders and management teams.

Forbion is a dedicated life sciences venture capital firm. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. The company manages well over €1.8 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of 24 life sciences investment professionals and has successful investments in over 80 companies. The firm is a signatory to the United Nations Principles for Responsible Investment and besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients.

Blue Owl Healthcare Opportunities manages a series of investment funds focused on equity investments in healthcare companies across the biopharma, diagnostics, and digital health sectors. Blue Owl Healthcare Opportunities is an investment strategy within Blue Owl Capital.

Novartis Venture Fund is a financially driven corporate life science venture fund whose purpose is to foster innovation, drive significant patient benefit and generate superior returns by creating and investing in innovative life science companies at various stages of their development.

Pfizer Ventures, the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. Pfizer Ventures seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.

Pontifax is a healthcare-dedicated venture capital firm with US$1.2 billion under management, which was founded in 2004. We seek transformative, cutting-edge life sciences technologies at all development stages. Our portfolio comprises of about 100 companies that develop breakthrough solutions to substantial unmet needs.

UZH Life Sciences Fund AG (UZH LSF) invests in life science spin-offs from the University of Zurich (UZH) that are in an early stage of development. This accelerates the transfer of research results from the UZH into practice. The UZH LSF is a funding instrument established jointly by the UZH Foundation and the Novartis Venture Fund in 2016.

BaseLaunch is a venture creation and development platform that helps scientists and entrepreneurs launch and build exceptional biotech companies, from inception through to Series A funding. Since 2018, BaseLaunch supported ventures have raised in total over US$390 million. BaseLaunch is operated in partnership with leading global pharma companies and venture funds and managed by Basel Area Business & Innovation, the innovation and investment promotion agency for the Basel Area.